HUMANIZED MOUSE MODELS: APPLICATIONS IN ONCOLOGY AND INFECTIOUS DISEASE

New immunotherapies are generating unprecedented clinical response. However, immune activation by I/O agents can also cause notable and potentially fatal clinical toxicity, such as cytokine storms, which is not observed in preclinical studies. Immuno-safety has therefore become a major clinical concern, which needs to be sufficiently addressed in early preclinical drug development.

There are over 7000 rare diseases worldwide, and unfortunately, less than five percent have an FDA approved therapy. The lack of valid animal models remains one of the biggest hurdles for preclinical drug discovery for rare diseases. However, recent technology advances can enable the development of innovative rodent models to speed up the drug discovery process.

COPAN Diagnostics is pleased to release presentations given at an event held during ASM Microbe 2023. During this popular live event guests learned about the benefits of using technology for improved laboratory results and faster turnaround times.

Leukemia and lymphoma are hematologic neoplasms that affect members of all age groups. Each year, over 140,000 people in the US are diagnosed with a hematologic malignancy of some kind. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lymphomas and leukemias becomes more and more relevant to the survival of the patient, and immunohistochemistry has served as a key auxiliary test in determining these diagnoses. This presentation covers many of the basic science, facts, and statistics of hematologic malignancies, as well as the utility of immunohistochemical testing with markers such as CD20, PAX-5, CD61, CD71, Cyclin D1, and SOX-11 in the accurate diagnosis and survival rates of lymphoma and leukemia.